Sirolimus Oral Solution Recalled for Failed Dissolution Specifications
Apotex Corp. recalls Sirolimus Oral Solution lot RZ1598 for exceeding dissolution specifications at the 14-month timepoint. Approximately 2,353 bottles were distributed nationwide.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: This is an FDA Class III recall with no reported illnesses or injuries. The hazard is a manufacturing quality defect (failed dissolution specifications) without documented harm, making this a precautionary recall.
Plain-English summary
Apotex Corp. is recalling Sirolimus Oral Solution (1 mg/mL, 60 mL bottles) lot RZ1598 (expiration date 02/2023) due to failed dissolution specifications. During testing at the 14-month timepoint, this lot exceeded the specification limit for dissolution.
Sirolimus is a prescription immunosuppressant medication used in transplant recipients. The recall affects 2,353 bottles that were distributed nationwide in the United States.
Patients or caregivers with this medication should contact their healthcare provider or pharmacist for guidance regarding this recall.
The recalled product
- Product
- SIROLIMUS (SIROLIMUS)
- Brand
- SIROLIMUS
- Manufacturer
- Apotex Corp.
- Category
- Drug
- Hazard
- dissolution-failure
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot: RZ1598
- exp. date 02/2023
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · SIROLIMUS
- ModeratePrescription Drug Sirolimus Recalled for Failed Impurity Specifications
FDA (Drugs) · 2024-05-29
- ModerateSirolimus Tablets Recalled for Failed Impurities and Degradation Specifications
FDA (Drugs) · 2021-09-29
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27